Drug Repurposing Research
rareSHIFT™ offers patients, families, and foundations access to Unravel Biosciences’ cutting edge BioNAV™ AI drug discovery platform, custom animal models, and clinical translation. We offer two popular standard services that are designed specifically to meet the immediate repurposing research needs of rare disease patients. The aim of rareSHIFT™ is to provide patients with data within a few months to support research for initial treatments using readily-available drugs.
We further offer a full suite of customizable drug discovery and development services that builds on initial personalized discovery, from personalized animal model development to formal clinical trials, and have partnered with families and foundations to customize their multi-phase drug discovery strategy. See our FAQ section for more details on how we work and our many successes to-date.
NOTE: Provided research services and resulting data are FOR RESEARCH AND INFORMATIONAL USE ONLY and not intended to diagose or treat disease
Standard Services
For research use only. Reports and data require additional evaluation and drug development and are not reviewed by a clinician. We also offer a full suite of custom R&D and clinical research services as a dedicated partner from discovery to clinical impact.
Personalized Repurposing Research
Personalized drug prediction (1 patient, 1 healthy control) from the comfort of your home anywhere in the world to generate repurposing leads for further research. Services are run in batches of 10+ patients and typically take 2 months once samples are returned form all 10 patients. Any diagnosis (or lack of a diagnosis) welcome.
Price: $14,000
(per patient)
What you receive:
At-home sample collection kits with return envelope.
RNAseq data from 1 patient and matching control collected over 2 days that can power other research.
Personalized repurposing drug candidate list that can be used for further research (additional development services below).
Personalized analysis of potential therapeutic mechanisms.
Patient Group Repurposing Research
Analyze patient populations (20+ patients and 20+ healthy controls) anywhere in the world. This precision medicine approach identifies repurposing candidates for patient groups rather than a fully personalized program and takes approximately 3 months. Scaled for foundation-led research programs.
Price: $66,500
(per 20 patients + $1,900/additional patient)
What you receive:
At-home sample collection kits with return envelope.
Anonymized RNAseq data from 20+ patients and 20+ matching controls collected at a single timepoint that can power other research.
Patient stratification groups, each with a repurposing candidate list and likely therapeutic mechanisms that can be used for further development and research.
Mother of boy with KMT2B dystonia
“Based on the data we gathered in his report, our doctor began off-label drug testing. Since starting his medication, our son has experienced significant positive changes. His teachers and service providers report a marked improvement in his ability to focus, his receptive language is returning, he is sleeping better, and he no longer seems to be driven by a "motor" that could not be slowed down. While we are still early in the process, I can confidently say that the results we received were worth every penny. There is so little information available about these rare diseases, so having the opportunity to collaborate with researchers who invest time in understanding your child's specific condition is truly invaluable.”
Custom Services
SquishyWare™: patient-specific animal models in weeks
Our automated screening platform, SquishyWare™, uses thousands of CRISPR-engineered tadpoles together with cutting edge computer vision analysis to validate hits that halt or reverse disease in a whole organism, letting us ask clinically-relevant questions from the start. We routinely use tadpole models to screen drugs for seizure, neurological, muscle, psychiatric, and sleep disorders.
Mouse studies to generate IND-enabling data
We partner with the world’s best mouse model experts to deliver data to support clinical translation.
Clinical trial development and execution focusing on N-of-1 design
We use the off-target effects of existing, approved drugs to validate discovered drug targets in patients in the clinic, and in parallel develop new, highly effective therapies. This phase is conducted under applicable laws and regulations pertaining to clinical research and drug candidate trials and only following approval by relevant regulatory agencies. Unravel supports trial design, regulatory filings, and clinical trial studies.
“The good physician treats the disease; the great physician treats the patient who has the disease.”
— William Osler, “Father of Modern Medicine”